Document Detail


Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease.
MedLine Citation:
PMID:  18343648     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Dyspnea and functional limitation in interstitial lung diseases (ILD) are not always adequately explained by the degree of compromise in pulmonary function alone. Pulmonary hypertension (PH) is felt to be a major contributor to morbidity and mortality in these patients. It is not clear whether treatment with newer vaso-active agents benefits patients with PH in the setting of moderate or severe ILD.
METHODS: Medical records of patients followed at our institution between July 2001 and June 2005 were reviewed to identify patients with moderate or severe fibrotic ILD and PH. Data regarding demographics, hemodynamics, and clinical characteristics at baseline and during follow-up were collected.
RESULTS: We identified 19 patients who met our inclusion criteria and in whom vaso-active therapy [epoprostenol (N=10), bosentan (N=9)] was initiated. Most patients [(15/19(79%)] showed an initial positive response to therapy and improved their 6-min walk distance (6MWD) by >50m (responders) and 12/15 (80%) improved by at least 1 WHO functional class. At 1-year follow-up, 7 of 15 (47%) 'responders' had deteriorated significantly. None of the patients died during 1 year of follow-up.
CONCLUSIONS: Epoprostenol and bosentan produced short-term functional benefit in our patients with PH and moderate or severe restrictive ILD. The generalizability of these results awaits the results of larger, prospective, randomized trials in such patients.
Authors:
Omar A Minai; D Sahoo; J T Chapman; A C Mehta
Related Documents :
6931668 - Early detection of busulfan lung: report of a case.
17437168 - Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active int...
21050538 - Increased alveolar nitric oxide in early systemic sclerosis.
2414988 - Pulmonary strongyloidiasis. diagnosis by sputum gram stain.
22783398 - Correlation of histone methyl marks with circulating nucleosomes in blood plasma of can...
8480688 - Zinc distribution in blood components, inflammatory status, and clinical indexes of dis...
Publication Detail:
Type:  Journal Article     Date:  2008-03-17
Journal Detail:
Title:  Respiratory medicine     Volume:  102     ISSN:  0954-6111     ISO Abbreviation:  Respir Med     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-06-13     Completed Date:  2008-11-03     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  8908438     Medline TA:  Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  1015-20     Citation Subset:  IM    
Affiliation:
Department of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA. minaio@ccf.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / therapeutic use
Epoprostenol / therapeutic use
Exercise Tolerance / physiology*
Female
Humans
Hypertension, Pulmonary / drug therapy*
Lung Diseases, Interstitial / drug therapy*
Male
Middle Aged
Retrospective Studies
Sulfonamides / therapeutic use
Treatment Outcome
Vasodilator Agents / therapeutic use*
Walking / physiology*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Sulfonamides; 0/Vasodilator Agents; 35121-78-9/Epoprostenol; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Variation in severity and type of sleep-disordered breathing throughout 4 nights in patients with he...
Next Document:  Time to desaturation in the 6-min walking distance test predicts 24-hour oximetry in COPD patients w...